Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3H2101
Tue, 24.09.2024
aap Implantate AG
BfArM and lead ethics committee approve early end of recruitment
Last patient included on 6 August 2024;
A total of 202 patients were included in the study;
Start of the MDR registration phase
aap Implantate AG ("aap" or "Company") informs that due to the ongoing good results the patient recruitment of the human clinical trial could be terminate [ … ]
Fri, 23.08.2024
aap Implantate AG
Financial year 2023 got off to a promising start for aap Implantate AG ("aap" or "Company"). Sales increased in all regions and exceeded the previous year's figures. The initial upswing lost momentum and the outlook in aap's sales markets gradually deteriorated due to financial difficulties in the healthcare sector and uncertainties about further e [ … ]
Wed, 14.08.2024
aap Implantate AG
Sales: H1/2024 increased by 10% to EUR 6.4 million compared to H1/2023; main growth driver EMEA region
EBITDA: H1/2024 breaks even, Trauma achieves positive EBITDA
aap Implantate AG ("aap" or "Company") looks back on a pleasing first half-year. The Company was able to increase sales and EBITDA compared to the previous year and generate a positive [ … ]
Thu, 23.05.2024
aap Implantate AG
Notice to the Holders of the Mandatory Convertible Bond 2023/2028
(ISIN: DE000A351ZH9 / WKN: A351ZH)
aap Implantate AG announces today that the resolution adopted in the vote held without a meeting from March 26, 2024, to March 28, 2024, to cancel the vesting period regarding the conversion of the bonds and to allow a first-time conversion ri [ … ]
Mon, 22.04.2024
aap Implantate AG
Sales increase by 5.6% compared to the same quarter of the previous year
Major order and parts of Q1 sales form strong basis for growth in Q2
Human clinical trial of the innovative antibacterial implant technology is progressing positively and opens up the possibility of an earlier conclusion
aap Implantate AG ("aap" or "Company") continued it [ … ]
Fri, 19.04.2024
aap Implantate AG
The premium to the current share price of EUR 0.8 amounted to 37.5%
The cash inflow will strengthen the company's own resources for the ongoing human clinical trial of the innovative antibacterial implant technology
aap Implantate AG ("aap" or "Company") successfully completed the 10% capital increase announced on March 18, 2024 with exclusion [ … ]
Wed, 17.04.2024
aap Implantate AG
Publication of inside information in accordance with Article 17 of Regulation (EU) No 596/2014
aap postpones publication of the consolidated financial statements 2023 due to staff shortages
Berlin, 17. April 2024, time: 6:25 pm
aap Implantate AG ("aap" or "Company") postpones the publication of the annual financial report for the financial [ … ]
Wed, 03.04.2024
aap Implantate AG
86.03% of the nominal amount and the votes of all outstanding bonds participated in the vote
Approval by 100% of the votes cast
aap Implantate AG ("aap" or "Company") successfully completed the vote without a meeting of bondholders on an amendment to the terms and conditions of the Bonds with an approval of 100% of the votes cast and the nominal v [ … ]
Mon, 18.03.2024
aap Implantate AG
Publication of inside information pursuant to Article 17 of Regulation (EU) No 596/2014
The Management Board of aap Implantate AG ("Company") resolved today, with the approval of the Supervisory Board, to increase the Company's share capital against cash contributions by issuing new no-par value bearer shares with a pro rata amount of the share c [ … ]
Tue, 05.03.2024
aap Implantate AG
aap Implantate AG ("aap" or "Company") proposes to the creditors of the mandatory convertible bond 2023/2028 (ISIN: DE000A351ZH9 / WKN: A351ZH) traded on the open market of the Frankfurt Stock Exchange to resolve on an amendment to the terms and conditions of the bond by way of a vote without a meeting of bondholders. The amendment to the terms and [ … ]